Arcadia Biosciences Reports Q2 and H1 2026 Financial Results

What Happened

• On August 13, 2026 Arcadia Biosciences, Inc. announced its financial results for the second quarter and first half of 2026 in a press release. The company furnished the press release (Exhibit 99.1) and accompanying financial information tables (Exhibit 99.2) with this Form 8‑K. The report was signed by CEO Thomas J. Schaefer.

Key Details

• Filing date: August 13, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Exhibits furnished: 99.1 (press release) and 99.2 (financial information tables).
• The information in the 8‑K and attached exhibits is furnished (not “filed”) and therefore is not subject to certain liabilities under Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.
• Report executed by Thomas J. Schaefer, Chief Executive Officer.

Why It Matters

• This 8‑K provides Arcadia’s most recent quarterly and year‑to‑date performance snapshot that investors use to assess revenue, profitability, cash position and operational trends.
• Investors should review the furnished exhibits (press release and financial tables) for the specific numbers and metrics; the 8‑K itself confirms the timing and availability of those results but does not add additional financial detail beyond the exhibits.